Why did FDA refuse Moderna’s flu shot?
What regulators said and what it could mean
U.S. regulators declined to accept the company’s application for an mRNA-based influenza vaccine, citing problems with the way the company conducted its trial and what it chose as the comparator. The agency’s reviewers concluded the shot was not compared to the best available standard of care, a procedural and scientific concern that led the Food and Drug Administration to refuse to move forward with a formal review.
The decision was made at senior levels inside the agency. According to reporting, a top FDA official, Vinay Prasad, overruled the views of some agency reviewers in issuing the refusal. Moderna has said it plans to request a meeting with the FDA to discuss the agency’s decision and next steps.
Why this matters - Other developers: The ruling could set a precedent for how clinical trials for updated or new influenza vaccines must be designed and which comparators are acceptable. That affects not only Moderna but other companies pursuing mRNA or novel flu platforms. - Timing and access: A refusal to review delays any potential U.S. authorization, which could slow the availability of a new flu vaccine option that manufacturers argue might improve protection. - Agency credibility and internal debate: The move attracted criticism from some clinicians and scientists who saw the refusal as surprising; it also drew internal attention because it involved senior-level intervention.
What is still unclear Exact technical details of the FDA reviewers’ scientific objections and the complete data Moderna submitted have not been fully summarized in the public reports. It is also unknown how long it will take for company and regulator to resolve the disagreement or whether Moderna will run additional analyses or trials.
Next steps likely include formal meetings between the company and the agency, and if the issues can be addressed, a resubmission or new application.